IL-32 gamma suppressed atopic dermatitis through inhibition of miR-205 expression via inactivation of nuclear factor-kappa B
IL-32γ suppressed atopic dermatitis through inhibition of miR-205 expression via inactivation of nuclear factor-kappa B
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- Nature IndexSCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY146(1) · pp.156 · 2020
- 피인용
- Web of Science 42Scopus 50
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 10.228
- ISSN
- 0091-6749
저자
- Lee, Yong Sun제1저자College of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea
- Han, Sang-BaeCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea
- Ham, Hyeon JooCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea
- Park, Ju HoCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea
- Lee, Jong SungCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea
- 황대연Department of Biomaterial Science, College of Natural Resources and Life Science/Life and Industry Convergence Research Institute, Pusan National University, Miryang, Korea
- 정영석College of Pharmacy, Pusan National University, Busan, Korea
- Yoon, Do Young교신저자Department of Bioscience and Biotechnology, Konkuk University, Seoul, Korea
- Hong, Jin Tae교신저자College of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea
초록
Background: IL-32 is a novel cytokine involved in many inflammatory diseases. However, the role of IL-32 gamma, an isotype of IL-32, in atopic dermatitis (AD) has not been reported. Objective: We investigated the effects of IL-32 gamma on development of AD and its action mechanisms. Methods: We used phthalic anhydride (PA) and an MC903-induced AD model using wild-type and IL-32 gamma transgenic mice. We conducted the therapy experiments by using recombinant IL-32 gamma protein in a reconstructed human skin model and PA-induced model. We conducted a receiver operating characteristic analysis of IL-32 gamma with new AD biomarkers, IL-31 and IL-33, in serum from patients with AD. Results: Dermatitis severity and epidermal thickness were significantly reduced in PA- and MC903-induced IL-32 gamma transgenic mice compared with in wild-type mice. The concentration of AD-related cytokines was reduced in PA- and MC903-induced IL-32 gamma transgenic mice compared with in wild-type mice. Subsequent analysis showed that IL-32 gamma inhibits miR-205 expression in PA- and MC903-induced skin tissue samples and TNF-alpha/IFN-gamma-treated HaCaT cells. IL-32 gamma reduced NF-kappa B activity in skin tissue samples from PA- and MC903-induced mice and TNF-alpha/IFN-gamma-treated HaCaT cells. NF-kappa B inhibitor treatment with IL-32 gamma expression further suppressed expression of inflammatory mediators as well as miR-205 in TNF-alpha/IFN-gamma-treated HaCaT cells. Furthermore, recombinant IL-32 gamma protein alleviated AD-like inflammation in in vivo and reconstructed human skin models. Spearman correlation analysis showed that serum levels of IL-32 gamma and miR-205 were significantly concordant in patients with AD. Conclusion: Our results indicate that IL-32 gamma reduces AD through the inhibition of miR-205 expression via inactivation of NF-kappa B.
키워드
Atopic dermatitisIL-32 gammamiR-205NF-kappa BTH2 RESPONSESUP-REGULATIONMURINE MODELINFLAMMATIONCELLSACTIVATIONMICRORNASCYTOKINESIL-32IL-1-BETAIL-32γNF-κB
식별자
- Scopus EID
- 2-s2.0-85078898386
- WoS UID
- 000579170500025



로그인
연구물 목록으로